Seven Fleet Capital Management LP Purchases 177,809 Shares of Agios Pharmaceuticals, Inc. $AGIO

Seven Fleet Capital Management LP boosted its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 560.2% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 209,547 shares of the biopharmaceutical company’s stock after acquiring an additional 177,809 shares during the quarter. Agios Pharmaceuticals comprises approximately 2.2% of Seven Fleet Capital Management LP’s portfolio, making the stock its 11th largest holding. Seven Fleet Capital Management LP’s holdings in Agios Pharmaceuticals were worth $7,089,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. acquired a new stake in Agios Pharmaceuticals in the fourth quarter valued at approximately $25,000. Assetmark Inc. raised its position in shares of Agios Pharmaceuticals by 37.9% during the fourth quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 362 shares during the period. NewEdge Advisors LLC bought a new position in shares of Agios Pharmaceuticals in the 1st quarter worth $40,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Agios Pharmaceuticals in the 4th quarter worth $49,000. Finally, Quantbot Technologies LP acquired a new stake in Agios Pharmaceuticals in the 3rd quarter valued at $79,000.

Analysts Set New Price Targets

A number of analysts have commented on AGIO shares. Citigroup boosted their price target on shares of Agios Pharmaceuticals from $46.00 to $52.00 and gave the company a “buy” rating in a research note on Friday. JPMorgan Chase & Co. reduced their price objective on shares of Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating for the company in a report on Thursday, June 11th. Truist Financial decreased their target price on shares of Agios Pharmaceuticals from $41.00 to $39.00 and set a “buy” rating for the company in a research report on Friday. HC Wainwright upped their target price on shares of Agios Pharmaceuticals from $52.00 to $55.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, June 24th. Five research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $40.88.

Agios Pharmaceuticals News Summary

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: Second-quarter revenue from mitapivat products Pyrukynd and Aqvesme rose to $44.7 million from $12.5 million a year earlier, helped by Aqvesme’s U.S. launch in thalassemia. The company reported 442 cumulative prescriptions as of June 30. Agios second-quarter financial results
• Positive Sentiment: Agios reported a narrower quarterly loss than the Zacks consensus estimate, while management highlighted continued development of its hematology pipeline. The company also has $964.8 million in cash, cash equivalents and marketable securities to fund commercialization and research programs. Agios Q2 earnings report
• Positive Sentiment: The FDA granted priority review to mitapivat’s supplemental application in sickle cell disease, with a November 1, 2026 decision date. Approval could expand the drug’s addressable market. Agios also expects $45 million to $50 million in 2026 revenue from pyruvate kinase deficiency. Agios revenue outlook and sickle cell review
• Neutral Sentiment: HC Wainwright maintained a Buy rating and a $55 price objective while slightly raising its long-term 2030 EPS forecast. The forecast change supports the longer-term outlook but has limited immediate impact. Agios analyst estimates
• Negative Sentiment: Agios remains deeply unprofitable. Its reported quarterly loss of $1.69 per share was slightly worse than one analyst consensus estimate of $1.65, underscoring continued earnings risk despite revenue growth. Agios earnings results
• Negative Sentiment: Truist lowered its price target from $41 to $39, although it retained a Buy rating. Separately, Pomerantz announced an investigation into potential investor claims, creating an additional headline and legal overhang. Truist price target update

Agios Pharmaceuticals Trading Down 8.3%

Shares of Agios Pharmaceuticals stock opened at $30.02 on Friday. The company has a market capitalization of $1.79 billion, a P/E ratio of -4.28 and a beta of 0.54. The stock has a fifty day simple moving average of $34.48 and a 200 day simple moving average of $30.88. Agios Pharmaceuticals, Inc. has a 12-month low of $22.24 and a 12-month high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 34.40%. The company had revenue of $44.75 million for the quarter, compared to the consensus estimate of $26.39 million. On average, analysts predict that Agios Pharmaceuticals, Inc. will post -6.12 EPS for the current year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.